Results 81 to 90 of about 16,389 (183)

Associations between TMEM106B C‐terminal fragment aggregation, age, and TDP‐43 or tau pathology

Brain Pathology, Volume 36, Issue 5, September 2026.
TMEM106B C‐terminal fragment (CTF) aggregation represents an age‐associated, common, diffuse phenomenon emerging after midlife with a weak association with TDP‐43 or tau pathology. These findings suggest that TMEM106B fibrillization may define a distinct axis of protein aggregation in the aging human brain. Abstract Transmembrane protein 106B (TMEM106B)
Albert Acewicz, Sylwia Tarka, Michał Grzegorczyk, Radosław Rzepliński, Teresa Wierzba‐Bobrowicz, Tomasz Stępień   +5 more
wiley   +1 more source

Patterns of Dysgraphia in Primary Progressive Aphasia Compared to Post-Stroke Aphasia

Behavioural Neurology, 2013
We report patterns of dysgraphia in participants with primary progressive aphasia that can be explained by assuming disruption of one or more cognitive processes or representations in the complex process of spelling.
Andreia V. Faria, Jenny Crinion, Kyrana Tsapkini, Melissa Newhart, Cameron Davis, Shannon Cooley, Susumu Mori, Argye E. Hillis   +7 more
doaj   +1 more source

Temporal order of clinical, imaging, and biomarker changes in frontotemporal lobar degeneration–associated syndromes

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract BACKGROUND The temporal sequence of clinical, imaging, and biological changes in sporadic frontotemporal lobar degeneration (FTLD)–associated syndromes remains poorly characterized, and a comprehensive biomarker cascade model is lacking. METHODS We developed a data‐driven biomarker cascade model in 489 patients across the FTLD spectrum (211 ...
Alberto Benussi, Valeria Bracca, Enrico Premi, Valentina Cantoni, Federica Palacino, Aurora Saccavini, Maria Sofia Cotelli, Giuliano Binetti, Rosa Manenti, Antonella Alberici, Roberto Gasparotti, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Roberta Ghidoni, Barbara Borroni   +15 more
wiley   +1 more source

Sensory Neuroscience—Charting the Course From Molecular Mechanisms to Clinical Translation

Sensory Neuroscience, EarlyView.
Renjie Chai
wiley   +1 more source

Multimodel Diffusion MRI Signatures in Atypical Parkinsonian Disorders

Human Brain Mapping, Volume 47, Issue 11, 01 August 2026.
We implemented a diffusion MRI framework to analyze clinically compatible multishell data across 123 participants, including controls, Parkinson's disease (PD), corticobasal syndrome (CBS), and progressive supranuclear palsy Richardson's syndrome (PSP‐RS). Diffusion models included DTI, free‐water elimination (FWE), NODDI, and fixel‐based analysis (FBA)
Yuqi Tian, Farwa Ali, Mary M. Machulda, Val. J. Lowe, Keith A. Josephs, Jennifer L. Whitwell   +5 more
wiley   +1 more source

Feasibility of convection‐enhanced delivery of unlabeled 225Ac for glioblastoma: Transport, dosimetry, and clonogenic survival modeling

Medical Physics, Volume 53, Issue 8, August 2026.
Abstract Background Glioblastoma (GB) is an aggressive primary brain tumor with local recurrence rates exceeding 90% and a five‐year survival rate of approximately 5%. Standard treatments such as surgical resection, external beam radiotherapy (EBRT), and chemotherapy often leave residual tumor cells that are resistant to therapy.
Maram El Sabri, Leyla Moghaddasi, Puthenparampil Wilson, Frank Saran, Eva Bezak   +4 more
wiley   +1 more source

Biomarker‐Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease‐Modifying Treatments: A Consensus Statement by Belgian Experts

European Journal of Neurology, Volume 33, Issue 8, August 2026.
ABSTRACT Background The recent approval of disease‐modifying therapies (DMTs) for early Alzheimer's disease (AD) marks a major shift in clinical practice. Biomarker confirmation of amyloid pathology is now required alongside clinical assessment, and blood‐based tests are improving accessibility.
Tim Van Langenhove, Sara Van Mossevelde, Marijke Miatton, Jan De Lepeleire, Rose Bruffaerts, Jean Christophe Bier, Kurt Segers, Jurn Verschraegen, Mirko Petrovic, Manfredi Ventura, Haroun Jedidi, Ingo Beyer, Eric Mormont, Rik Vandenberghe, Aline Delva, Christian Gilles, Donatienne Van Weehaeghe, Gaëtane Picard, Peter De Deyn, Mélanie Strauss, Evert Thiery, Eric Salmon, Gert Cypers, Joris Vlaemynck, Katrin Gillis, Jan Versijpt, Maria Bjerke, Anne Sieben, Bernard Hanseeuw, Sebastiaan Engelborghs, Olivier Deryck, on behalf of the BeDeCo members   +31 more
wiley   +1 more source

Introduction to Primary Progressive Aphasia

Neurobiology of Language, 2022
Maria Luisa Gorno-Tempini, Peter Pressman   +1 more
doaj   +1 more source

Frontotemporal dementia and primary progressive aphasia, a review

Neuropsychiatric Disease and Treatment, 2014
Howard S KirshnerDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN, USAAbstract: Frontotemporal dementias are neurodegenerative diseases in which symptoms of frontal and/or temporal lobe disease are the first signs of the ...
Kirshner HS
doaj  

Essential Considerations for Diagnosing Primary Progressive Aphasia

Journal of Indian Speech Language & Hearing Association
Language impairments vary widely and are often linked to brain dysfunction. While classic aphasia usually occurs after brain injury, other conditions, such as primary progressive aphasia (PPA), occur due to neurodegeneration of the brain.
P. B. Jaya Lakshmi, S. Anusha Rao, G. Shirley Kerense Arockiamary, B. Nandhini   +3 more
doaj   +1 more source